Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. (603168.SS)
CNY 6.93
(0.14%)
CNY 6.93
(0.14%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 440.92 Million CNY | 82.96% |
| 2022 | 240.99 Million CNY | 3.48% |
| 2021 | 232.88 Million CNY | -36.51% |
| 2020 | 366.78 Million CNY | 265.75% |
| 2019 | 100.28 Million CNY | -40.1% |
| 2018 | 167.41 Million CNY | -21.08% |
| 2017 | 212.12 Million CNY | -14.43% |
| 2016 | 247.88 Million CNY | -35.34% |
| 2015 | 383.36 Million CNY | 250.29% |
| 2014 | 109.44 Million CNY | -55.19% |
| 2013 | 244.25 Million CNY | 0.8% |
| 2012 | 242.32 Million CNY | 93.19% |
| 2011 | 125.43 Million CNY | 78.04% |
| 2010 | 70.45 Million CNY | -8.68% |
| 2009 | 77.14 Million CNY | 11.42% |
| 2008 | 69.23 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 431.27 Million CNY | -3.07% |
| 2024 Q1 | 423.29 Million CNY | -4.0% |
| 2024 Q2 | 444.94 Million CNY | 5.12% |
| 2023 Q1 | 261.6 Million CNY | 8.55% |
| 2023 Q4 | 440.92 Million CNY | 48.79% |
| 2023 FY | 440.92 Million CNY | 82.96% |
| 2023 Q3 | 296.34 Million CNY | 12.02% |
| 2023 Q2 | 264.55 Million CNY | 1.13% |
| 2022 Q4 | 240.99 Million CNY | 56.56% |
| 2022 Q3 | 153.92 Million CNY | 0.68% |
| 2022 Q2 | 152.89 Million CNY | -4.92% |
| 2022 Q1 | 160.79 Million CNY | -30.95% |
| 2022 FY | 240.99 Million CNY | 3.48% |
| 2021 Q4 | 232.88 Million CNY | 40.55% |
| 2021 Q1 | 347.11 Million CNY | -5.36% |
| 2021 FY | 232.88 Million CNY | -36.51% |
| 2021 Q2 | 143.67 Million CNY | -58.61% |
| 2021 Q3 | 165.69 Million CNY | 15.33% |
| 2020 Q3 | 85.67 Million CNY | 11.83% |
| 2020 Q1 | 70.02 Million CNY | -30.18% |
| 2020 FY | 366.78 Million CNY | 265.75% |
| 2020 Q4 | 366.78 Million CNY | 328.12% |
| 2020 Q2 | 76.61 Million CNY | 9.41% |
| 2019 Q2 | 128.94 Million CNY | -9.19% |
| 2019 Q4 | 100.28 Million CNY | -21.79% |
| 2019 FY | 100.28 Million CNY | -40.1% |
| 2019 Q1 | 141.99 Million CNY | -15.19% |
| 2019 Q3 | 128.22 Million CNY | -0.56% |
| 2018 Q2 | 108.82 Million CNY | -39.67% |
| 2018 Q4 | 167.41 Million CNY | 42.52% |
| 2018 Q3 | 117.46 Million CNY | 7.94% |
| 2018 FY | 167.41 Million CNY | -21.08% |
| 2018 Q1 | 180.38 Million CNY | -14.96% |
| 2017 Q3 | 191.07 Million CNY | 19.39% |
| 2017 FY | 212.12 Million CNY | -14.43% |
| 2017 Q4 | 212.12 Million CNY | 11.01% |
| 2017 Q2 | 160.05 Million CNY | -15.14% |
| 2017 Q1 | 188.59 Million CNY | -23.92% |
| 2016 Q1 | 424.47 Million CNY | 10.72% |
| 2016 Q2 | 464.04 Million CNY | 9.32% |
| 2016 Q4 | 247.88 Million CNY | -50.39% |
| 2016 Q3 | 499.66 Million CNY | 7.68% |
| 2016 FY | 247.88 Million CNY | -35.34% |
| 2015 Q2 | 143.61 Million CNY | 26.06% |
| 2015 Q1 | 113.92 Million CNY | 4.1% |
| 2015 FY | 383.36 Million CNY | 250.29% |
| 2015 Q4 | 383.36 Million CNY | 123.9% |
| 2015 Q3 | 171.22 Million CNY | 19.22% |
| 2014 Q2 | 276.2 Million CNY | 1.94% |
| 2014 Q1 | 270.94 Million CNY | 10.93% |
| 2014 FY | 109.44 Million CNY | -55.19% |
| 2014 Q4 | 109.44 Million CNY | 6.08% |
| 2014 Q3 | 103.17 Million CNY | -62.65% |
| 2013 Q4 | 244.25 Million CNY | 0.0% |
| 2013 FY | 244.25 Million CNY | 0.8% |
| 2013 Q1 | - CNY | 0.0% |
| 2012 FY | 242.32 Million CNY | 93.19% |
| 2011 Q3 | 104.69 Million CNY | 0.0% |
| 2011 FY | 125.43 Million CNY | 78.04% |
| 2011 Q4 | 125.43 Million CNY | 19.81% |
| 2010 FY | 70.45 Million CNY | -8.68% |
| 2009 FY | 77.14 Million CNY | 11.42% |
| 2008 FY | 69.23 Million CNY | 0.0% |